Leadership Overview
Shionogi & Co Ltd has 4 executives leading key functions including strategy, finance, and medical affairs.
Driven by a commitment to patient well-being, Shionogi & Co Ltd focuses on developing groundbreaking treatments for infectious diseases and other critical health challenges, aiming for global impact through scientific innovation and collaboration.
Driven by a commitment to patient well-being, Shionogi & Co Ltd focuses on developing groundbreaking treatments for infectious diseases and other critical health challenges, aiming for global impact through scientific innovation and collaboration.
Leadership Roles at Shionogi & Co Ltd
Takeshi Kasuya - Chief Executive Officer
Takeshi Kasuya, the Chief Executive Officer at Shionogi & Co Ltd, directs the overarching corporate strategy and operational execution. Kasuya guides the company's mission to develop innovative treatments that address urgent global health needs, particularly in infectious diseases. This leadership involves fostering a culture of scientific excellence and ensuring the efficient allocation of resources towards groundbreaking research and development initiatives. The Chief Executive Officer's purview extends to shaping the company's long-term vision and market positioning, driving forward the discovery and delivery of novel therapies for conditions such as HIV, influenza, and emerging viral threats. Kasuya's strategic direction ensures Shionogi & Co Ltd maintains its pioneering role in pharmaceutical innovation, leveraging both internal capabilities and external partnerships to accelerate therapeutic advancements and bring life-changing medicines to patients with precision and urgency.
Isao Teshirogi - Representative Director, President & Chief Executive Officer
Isao Teshirogi, the Representative Director, President & Chief Executive Officer at Shionogi & Co Ltd, spearheads the company's strategic direction and global operations. Teshirogi champions the core mission of developing innovative treatments to improve patient lives worldwide, with a particular emphasis on addressing pressing global health challenges like infectious diseases. This involves overseeing the discovery and delivery of novel therapies for conditions including antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. The President & Chief Executive Officer drives the integration of in-house research and development with strategic collaborations across industry, government agencies, biotech companies, and academic institutions. Isao Teshirogi's leadership ensures Shionogi & Co Ltd accelerates scientific programs and brings meaningful therapies to patients with the required urgency and precision, solidifying the company's position as a pioneer in pharmaceutical innovation.
Masahiro Fujita - Senior Vice President & Chief Financial Officer
Masahiro Fujita, the Senior Vice President & Chief Financial Officer at Shionogi & Co Ltd, manages the company's financial health and strategic resource allocation. Fujita oversees all financial planning, accounting, and reporting functions, ensuring fiscal discipline and transparency across the organization. This role is critical in supporting Shionogi & Co Ltd's dedication to developing innovative treatments by securing and managing the necessary capital for research and development. The Chief Financial Officer's responsibilities include optimizing financial strategies to support global operations and expansion, particularly in the pursuit of novel therapies for infectious diseases and other pressing health challenges. Masahiro Fujita's financial acumen guides investment decisions, enabling the company to pursue groundbreaking scientific programs and strategic collaborations with industry partners, government agencies, and academic institutions, thereby accelerating the delivery of life-changing medicines to patients worldwide.
Tsutae Nagata - Chief Medical Officer
Tsutae Nagata, the Chief Medical Officer at Shionogi & Co Ltd, directs the company's clinical development and medical affairs strategies. Nagata leads the scientific and clinical teams responsible for advancing novel therapies from discovery through regulatory approval, focusing on critical areas such as infectious diseases, including antibiotics, HIV, influenza, and emerging viral threats. The Chief Medical Officer ensures that Shionogi & Co Ltd's research and development programs align with patient needs and global health priorities, driving the urgent and precise delivery of innovative treatments. This involves overseeing clinical trial design, execution, and data analysis, as well as fostering collaborations with healthcare professionals and regulatory bodies. Tsutae Nagata's medical expertise is fundamental to Shionogi & Co Ltd's mission of improving patient lives worldwide by translating scientific breakthroughs into tangible therapeutic solutions.
Explore Leadership Teams in Manufacturing
PCI Pharma Services is an integrated full service provider to companies in the global healthcare industry. They offer services including analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage, and distribution. They are headquartered in Philadelphia, Pennsylvania with locations in the United States and Europe.
Company Leadership AF
KS
Amrutanjan Health Care Ltd specializes in pain and congestion management products, including aromatic balms, roll-ons, and sprays. Founded in 1893, the company is dedicated to enhancing people's well-being by combining natural extracts with scientific research to create effective, side-effect-free solutions. Their product range caters to various needs, including headache relief, body pain management, and women's hygiene. Amrutanjan aims to serve a global consumer base while maintaining a commitment to sustainability and social responsibility.
Company Leadership PD
MB
TJ
SN
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Founded in 2008, Ascendis Health is a health and wellness company. They are based in Johannesburg, South Africa.
Company Leadership CN
Pv
LM
DF
Frequently Asked Questions Regarding Shionogi & Co Ltd Top Executives and Leadership Team
